X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs ASTRAZENECA PHARMA - Comparison Results

LUPIN    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN ASTRAZENECA PHARMA LUPIN/
ASTRAZENECA PHARMA
 
P/E (TTM) x 40.8 122.4 33.3% View Chart
P/BV x 2.5 23.7 10.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 LUPIN   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-18
ASTRAZENECA PHARMA
Mar-18
LUPIN/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4651,278 114.6%   
Low Rs727883 82.4%   
Sales per share (Unadj.) Rs349.6228.4 153.1%  
Earnings per share (Unadj.) Rs5.610.4 53.6%  
Cash flow per share (Unadj.) Rs29.616.3 181.9%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs300.398.8 304.1%  
Shares outstanding (eoy) m452.0825.00 1,808.3%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.14.7 66.3%   
Avg P/E ratio x197.2104.2 189.2%  
P/CF ratio (eoy) x37.166.4 55.8%  
Price / Book Value ratio x3.610.9 33.4%  
Dividend payout %90.00-   
Avg Mkt Cap Rs m495,50227,008 1,834.7%   
No. of employees `00017.01.4 1,256.8%   
Total wages/salary Rs m28,6471,535 1,865.9%   
Avg. sales/employee Rs Th9,273.64,210.9 220.2%   
Avg. wages/employee Rs Th1,681.01,132.2 148.5%   
Avg. net profit/employee Rs Th147.4191.1 77.2%   
INCOME DATA
Net Sales Rs m158,0425,710 2,767.8%  
Other income Rs m1,504123 1,227.3%   
Total revenues Rs m159,5455,833 2,735.4%   
Gross profit Rs m31,475463 6,799.5%  
Depreciation Rs m10,859147 7,366.8%   
Interest Rs m2,0440-   
Profit before tax Rs m20,076438 4,583.7%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,6440-   
Tax Rs m2,885179 1,612.4%   
Profit after tax Rs m2,513259 969.7%  
Gross profit margin %19.98.1 245.7%  
Effective tax rate %14.440.8 35.2%   
Net profit margin %1.64.5 35.0%  
BALANCE SHEET DATA
Current assets Rs m122,0953,209 3,804.5%   
Current liabilities Rs m50,9562,070 2,462.2%   
Net working cap to sales %45.020.0 225.5%  
Current ratio x2.41.6 154.5%  
Inventory Days Days8572 116.9%  
Debtors Days Days12035 343.4%  
Net fixed assets Rs m129,876790 16,433.8%   
Share capital Rs m90450 1,808.4%   
"Free" reserves Rs m134,8662,419 5,574.6%   
Net worth Rs m135,7712,469 5,498.3%   
Long term debt Rs m64,2450-   
Total assets Rs m263,0544,605 5,711.9%  
Interest coverage x10.8NM-  
Debt to equity ratio x0.50-  
Sales to assets ratio x0.61.2 48.5%   
Return on assets %1.75.6 30.8%  
Return on equity %1.910.5 17.6%  
Return on capital %3.717.7 21.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,141300 17,740.4%   
Fx outflow Rs m19,3352,015 959.6%   
Net fx Rs m33,807-1,715 -1,970.8%   
CASH FLOW
From Operations Rs m17,51288 19,922.5%  
From Investments Rs m-14,073-94 15,034.9%  
From Financial Activity Rs m-14,921NA-  
Net Cashflow Rs m-11,482-6 201,433.3%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 0.3 3,766.7%  
FIIs % 31.9 15.7 203.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 9.1 111.0%  
Shareholders   98,259 12,856 764.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Related Views on News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 17, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS